Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

Pau Abrisqueta, Neus Villamor, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. García-Marco, Yolanda González, Felix Carbonell, Secundino Ferrer, Encarna Monzó, Isidro Jarque, Ana Muntañola, Mireia Constants, Lourdes Escoda, Xavier Calvo, Sabela Bobillo, José Bruno MontoroEmili Montserrat, Francesc Bosch

Research output: Contribution to journalArticleResearchpeer-review

49 Citations (Scopus)

Fingerprint Dive into the research topics of 'Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds